Abstract
The aim of this study was to compare the immune function of patients with cervical cancer and the cancer recurrence rate in patients treated with biological immune therapy combined with chemotherapy or with chemotherapy only. A total of 79 postoperative patients with cervical cancer participated in the present study. They were randomly divided into a control group and an experimental group. Patients in the control group were treated with cisplatin chemotherapy. Patients in the experimental group were treated with dendritic cell-cytokine-induced killer (DC-CIK) cells combined with cisplatin chemotherapy. The CD3+, CD4+, CD8+, CD16+, CD56+ and CD4+CD25+ cell ratios in peripheral blood, and the expression levels of perforin, granzyme B (GraB) and CD107a of peripheral blood mononuclear cells (PBMCs) in all patients prior to and following treatment were observed. The changes of immune function and recurrence rate between these two groups prior to and following treatment were compared. Prior to treatment, the lymphocyte ratio had no significant difference between the two groups (P>0.05). Following treatment, the lymphocyte ratio in the experimental group was significantly higher than that in the control group (P<0.05). The positive expression levels of perforin, GraB and CD107a of PBMCs in the experimental group following treatment were significantly higher than those prior to treatment and those of the control group (P<0.05). The cumulative recurrence rate in the experimental group was significantly lower than that in the control group (P<0.05). In conclusion, in postoperative patients with cervical cancer, treatment with DC-CIK cells combined with cisplatin chemotherapy significantly improved the immune function, reduced the recurrence rate and prolonged the survival time of the patients.
Highlights
Cervical cancer is one of the most common gynecologic malignant tumors
Through comparing the efficacy of chemotherapy alone with that of biological immune therapy combined with chemotherapy on patients with cervical cancer, the current study explored the effectiveness of CHEN et al: BIOLOGICAL IMMUNE THERAPY COMBINED WITH CHEMOTHERAPY FOR CERVICAL CANCER
The patients of the control group were treated with chemotherapy, while the patients of the experimental group were treated with biological immune therapy combined with chemotherapy
Summary
Cervical cancer is one of the most common gynecologic malignant tumors. It mainly results from chronic infection with human papillomavirus (HPV), which leads to abnormal metaplasia and subsequent cancer. The application of biological treatment technology in tumor immunotherapy has been constantly expanding and gradually accepted by medical personnel and patients. This technology has become the fourth main treatment option for tumors, following surgery, radiotherapy and chemotherapy. Dendritic cells (DCs) are currently the most powerful antigen‐presenting cells (APCs) that have been discovered. Clinical studies concerning the use of biological immunotherapy in the treatment of cancer have been increasing; few of them have focused on cervical cancer [9]. Through comparing the efficacy of chemotherapy alone with that of biological immune therapy combined with chemotherapy on patients with cervical cancer, the current study explored the effectiveness of CHEN et al: BIOLOGICAL IMMUNE THERAPY COMBINED WITH CHEMOTHERAPY FOR CERVICAL CANCER immunotherapy combined with chemotherapy on the immune function of patients with cervical cancer and the recurrence rate of the cancer
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
